Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELVN-002 combinations in advanced HER2-positive solid tumors
2023-509716-29-00Phase 2Completed
- Sponsor
- Enliven Therapeutics
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of elvn-002 in Nonhematologic neoplasms, colorectal cancer (CRC) and breast cancer (5 arms), sponsored by Enliven Therapeutics. Started Aug 2024; status: completed.
02
Drugs
elvn-002
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)breast cancer
Beyond the preview
Go deeper on 2023-509716-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509716-29-00.